ThromboGenics NV News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.09.20	Oxurion NV Business Update - H1 2020 (GlobeNewswire)
14.09.20	Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference (GlobeNewswire)
11.09.20	Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September (GlobeNewswire)
01.09.20	Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) (GlobeNewswire)
03.08.20	Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
07.05.20	Oxurion NV Business Update - Q1 2020 (GlobeNewswire)
12.03.20	Oxurion NV Business Update – FY 2019 (GlobeNewswire)
09.02.20	Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME,at Angiogenesis, Exudation, and Degeneration 2020 Conference (GlobeNewswire)
05.02.20	Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 20 (GlobeNewswire)
19.12.19	Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME (GlobeNewswire)
18.10.19	Oxurion NV Business Update – Q3 2019 (GlobeNewswire)
09.10.19	Oxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco (GlobeNewswire)
09.09.19	Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME (GlobeNewswire)
05.09.19	Oxurion NV Business Update – H1 2019 (GlobeNewswire)
04.09.19	Oxurion Completes Enrolment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME) (GlobeNewswire)
02.09.19	Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019 (GlobeNewswire)
20.08.19	Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME (GlobeNewswire)
01.07.19	Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment (GlobeNewswire)
11.06.19	ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies (GlobeNewswire)
06.06.19	Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting (GlobeNewswire)
08.05.19	Oxurion NV : Oxurion NV Business Update - Q1 2019 (GlobeNewswire)
24.04.19	Oxurion NV announces full enrollment in its Phase 1 trial evaluating the safety of its plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule (GlobeNewswire)
04.04.19	Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME, ahead of schedule (GlobeNewswire)
07.03.19	Oxurion NV Business Update - FY 2018 (GlobeNewswire)
28.02.19	Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting (GlobeNewswire)
04.02.19	Oxurion NV to Present at the 2019 BIO CEO & Investor Conference (GlobeNewswire)
19.12.18	Oxurion NV to Present at 2019 Biotech Showcase[TM] Conference and Participate in CEO Power Breakfast Roundtable During the 37th Annual J.P. Morgan Healthcare Conference (PR Newswire)
19.12.18	Oxurion NV to Present at 2019 Biotech Showcase[TM] Conference and Participate in CEO Power Breakfast Roundtable During the 37th Annual J.P. Morgan Healthcare Conference (PR Newswire)
05.11.18	Oxurion and Beta Therapeutics to Develop New Heparanase Inhibitors for Treatment of dry AMD (PR Newswire)
05.11.18	Oxurion and Beta Therapeutics to Develop New Heparanase Inhibitors for Treatment of dry AMD (PR Newswire)
29.10.18	Oxurion NV Announces the Appointment of Adrienne Graves to Its Board of Directors (PR Newswire)
29.10.18	Oxurion NV Announces the Appointment of Adrienne Graves to Its Board of Directors (PR Newswire)
19.10.18	Oxurion NV Business Update - Q3 2018 (GlobeNewswire)
20.09.18	Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) (GlobeNewswire)
20.09.18	Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) (GlobeNewswire)
17.09.18	Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria (GlobeNewswire)
10.09.18	Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Websit (GlobeNewswire)
06.09.18	ThromboGenics Business Update - H1 2018 (GlobeNewswire)
03.09.18	ThromboGenics becomes "Oxurion" (GlobeNewswire)
19.07.18	ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) (GlobeNewswire)
27.06.18	ThromboGenics Plans Name Change to "Oxurion" (GlobeNewswire)
21.06.18	ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC (GlobeNewswire)
25.05.18	ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) (GlobeNewswire)
23.05.18	ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 (GlobeNewswire)
09.05.18	ThromboGenics Business Update - Q1 2018 (GlobeNewswire)
27.04.18	ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME) (GlobeNewswire)
06.04.18	ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149, a plasma kallikrein inhibitor, in Diabetic Macula Edema (GlobeNewswire)
04.04.18	ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME) (GlobeNewswire)
15.03.18	ThromboGenics Business Update - FY 2017 (GlobeNewswire)
08.12.17	Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	535.60	0.87 %	K V
Sonova Hldg	306.60	0.66 %	K V
Novartis	92.26	0.36 %	K V
Roche Hldg G	252.20	0.32 %	K V
Alcon	77.82	0.26 %	K V
ABB	49.20	-0.69 %	K V
UBS Group	27.56	-0.72 %	K V
CieFinRichemont	121.35	-0.82 %	K V
Sika	226.40	-0.96 %	K V
Logitech Intl	70.64	-1.86 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ThromboGenics NV

Aktien Top/Flop

Meistgelesene Nachrichten